Evidence map›Paper›PMID 42542611›Full record

ArticleiScience2026

Jinfang Song, Yi Xu, Yongru Zhuang, Tingting Yang, Ya Chen, Changjiang Ying, Qian Lu, Tao Wang, Xiaoxing Yin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jinfang SongDepartment of Pharmacy, Affiliated Hospital of Jiangnan University, Jiangnan University, Wuxi, China.
Yi XuPhase I Clinical Trial Center, Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang, China.
Yongru ZhuangDepartment of Pharmacy, Affiliated Hospital of Jiangnan University, Jiangnan University, Wuxi, China.
Tingting YangJiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China.
Ya ChenDepartment of Endocrinology, Affiliated Hospital of Jiangnan University, Wuxi, China.
Changjiang YingDepartment of Endocrinology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Qian LuJiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China.
Tao WangJiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China.
Xiaoxing YinJiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dapagliflozin shows variable renoprotective efficacy in patients with type 2 diabetic kidney disease (T2DKD). A retrospective clinical analysis confirmed marked interindividual variability in its urinary protein-lowering effects. To investigate the mechanism, drug affinity responsive target stability (DARTS) combined with quantitative proteomics was applied for target identification. Subsequent

Indexed as

dapagliflozingene polymorphismsGSK3Bindividual variabilitypodocytestype 2 diabetic kidney disease

Identifiers

PMID42542611
PMCPMC13427657

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.